"They indicated that they hadn't seen any evidence of hospitals...

"They indicated that they hadn't seen any evidence of hospitals working down current inventory in anticipation of GO approval."

I should have made clearer that my post was my opinion, based on having read all of the public written announcements by Avita (perhaps they have provided more detailed verbal updates, which I have not heard?). It has been my expectation that any price-sensitive information, such as hospitals not running down inventory, should be included in the written announcements. The most pertinent of their written announcements was:

"The revision in guidance is attributable to a slower-than-expected conversion rate of new accounts for our expanded label of full-thickness skin defects" in their April 10th Q1 update. To me, this statement does not appear to be a sufficient explanation of the sudden drop-off in growth rates.

Avita said nothing about changes in sales to the existing burns centers, but it appears to me that there was also a sudden and significant change in the sales growth rates for burns centers. Also, could one of several reasons for the slower than expected sign-on of new trauma centers be that some of them are holding off so they can start with the new Go product when it is finally approved?

If I have missed something, I would be grateful for any information relating to this, verbal or written.